HomeCompareMYMD vs PEP

MYMD vs PEP: Dividend Comparison 2026

MYMD yields 110.50% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYMD wins by $5.79M in total portfolio value
10 years
MYMD
MYMD
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full MYMD calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — MYMD vs PEP

📍 MYMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYMDPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYMD + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYMD pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYMD
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, MYMD beats the other by $1,760,311.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYMD + PEP for your $10,000?

MYMD: 50%PEP: 50%
100% PEP50/50100% MYMD
Portfolio after 10yr
$3.04M
Annual income
$1,097,353.28/yr
Blended yield
36.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

MYMD
No analyst data
Altman Z
-5.6
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYMD buys
0
PEP buys
0
No recent congressional trades found for MYMD or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYMDPEP
Forward yield110.50%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$5.93M$141.9K
Annual income after 10y$2,132,830.87$61,875.67
Total dividends collected$5.35M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MYMD vs PEP ($10,000, DRIP)

YearMYMD PortfolioMYMD Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$21,750$11,049.72$10,849$509.42+$10.9KMYMD
2$45,733$22,460.60$11,969$750.47+$33.8KMYMD
3$93,072$44,137.91$13,500$1,124.14+$79.6KMYMD
4$183,537$83,949.70$15,680$1,721.66+$167.9KMYMD
5$351,102$154,717.47$18,929$2,715.34+$332.2KMYMD
6$652,287$276,608.54$24,023$4,450.80+$628.3KMYMD
7$1,178,220$480,272.57$32,510$7,669.92+$1.15MMYMD
8$2,071,454$810,758.34$47,709$14,093.60+$2.02MMYMD
9$3,548,616$1,332,160.25$77,415$28,083.48+$3.47MMYMD
10$5,929,850$2,132,830.87$141,922$61,875.67+$5.79MMYMD

MYMD vs PEP: Complete Analysis 2026

MYMDStock

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Full MYMD Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this MYMD vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYMD vs SCHDMYMD vs JEPIMYMD vs OMYMD vs KOMYMD vs MAINMYMD vs MOMYMD vs PMMYMD vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.